4.8.8.4Vertical

Transcranial Magnetic Stimulation (TMS)

Non-invasive brain stimulation devices treating depression.

Market snapshot

These figures describe Neurological & Neuromodulation Devices (4.8.8), the segment that Transcranial Magnetic Stimulation (TMS) sits within — not Transcranial Magnetic Stimulation (TMS) on its own.

FragmentationConsolidatedEstimate

Within electromedical apparatus (NAICS 334510); the Census Bureau does not split out neuromodulation, so the segment is not separately sized.

Business model & economics

Revenue model

Implantable device sales plus replacement and programming

Key economics

Recurring revenue
Moderate

replacement-cycle-driven

EBITDA margin
20–30%
Capex intensity
High

Characteristics

  • Chronic-pain and movement-disorder applications.
  • Expanding neuromodulation indications.
  • Implantables with replacement-cycle revenue.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Neuromodulation strategics
  • Diversified medtech platforms
  • VC-backed innovators

What’s driving deals

  • Acquisition of neuromodulation innovation.
  • Expanding indications and chronic-pain demand.
  • High-value implantable economics.

Find Transcranial Magnetic Stimulation (TMS) acquisition targets

Search Acquisera’s index for companies classified under Transcranial Magnetic Stimulation (TMS) (4.8.8.4) and build a targeted deal pipeline.

Search companies